# Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct06459687/  
OnCo record `nct06459687` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Socazolimab run by Lee's Pharmaceutical Limited in cervical cancer, now recruiting.

## Summary

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06459687 by Lee's Pharmaceutical Limited, with 440 participants planned, started 2024-11-28. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06459687
- Phase: 3
- Setting: Efficacy and Safety of Socazolimab Combined With Chemotherapy With or Without Bevacizumab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer: A Randomized, Double-blind, Placebo-controlled Phase III Study
- Sponsor: Lee's Pharmaceutical Limited
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT06459687: https://clinicaltrials.gov/study/NCT06459687

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Socazolimab](https://onco.cc/drugs/socazolimab/)
- companies: [Lee's Pharmaceutical](https://onco.cc/companies/lees-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06459687.json